Sentiment for Accelerate Diagnostics Inc (NASDAQ:AXDX)
Accelerate Diagnostics Inc (NASDAQ:AXDX) institutional sentiment increased to 3 in Q2 2017. Its up 1.63, from 1.37 in 2017Q1. The ratio is more positive, as 69 hedge funds increased or opened new positions, while 23 cut down and sold their holdings in Accelerate Diagnostics Inc. The hedge funds in our partner’s database now hold: 19.15 million shares, down from 19.70 million shares in 2017Q1. Also, the number of hedge funds holding Accelerate Diagnostics Inc in their top 10 positions was flat from 3 to 3 for the same number . Sold All: 10 Reduced: 13 Increased: 44 New Position: 25.
Accelerate Diagnostics, Inc. is an in vitro diagnostics firm engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The company has market cap of $1.17 billion. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify , infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It currently has negative earnings. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results.
The stock increased 1.93% or $0.4 during the last trading session, reaching $21.15. About shares traded. Accelerate Diagnostics Inc (NASDAQ:AXDX) has risen 147.12% since November 17, 2016 and is uptrending. It has outperformed by 130.42% the S&P500.
Analysts expect Accelerate Diagnostics Inc (NASDAQ:AXDX) to report $-0.31 EPS on February, 26.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.31 EPS. After having $-0.31 EPS previously, Accelerate Diagnostics Inc’s analysts see 0.00 % EPS growth.
Birchview Capital Lp holds 31.6% of its portfolio in Accelerate Diagnostics Inc for 2.18 million shares. Miura Global Management Llc owns 1.20 million shares or 7.19% of their US portfolio. Moreover, Selkirk Management Llc has 6.2% invested in the company for 400,000 shares. The Minnesota-based Next Century Growth Investors Llc has invested 1.37% in the stock. Trellus Management Company Llc, a New York-based fund reported 29,186 shares.#img1#
Accelerate Diagnostics Inc (NASDAQ:AXDX) Ratings Coverage
Ratings analysis reveals 100% of Accelerate Diagnostics’s analysts are positive. Out of 4 Wall Street analysts rating Accelerate Diagnostics, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $17 while the high is $3400. The stock’s average target of $30.33 is 43.40% above today’s ($21.15) share price. AXDX was included in 8 notes of analysts from August 25, 2015. The firm earned “Buy” rating on Sunday, September 17 by Piper Jaffray. The firm has “Neutral” rating by BTIG Research given on Tuesday, August 25. As per Thursday, August 3, the company rating was maintained by Piper Jaffray. The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) has “Outperform” rating given on Friday, January 8 by William Blair. The company was maintained on Tuesday, August 9 by JP Morgan. BTIG Research reinitiated Accelerate Diagnostics Inc (NASDAQ:AXDX) on Wednesday, July 12 with “Buy” rating. The rating was initiated by JP Morgan on Thursday, March 24 with “Overweight”. The firm earned “Overweight” rating on Wednesday, December 16 by Piper Jaffray.
More important recent Accelerate Diagnostics Inc (NASDAQ:AXDX) news were published by: Globenewswire.com which released: “Accelerate Diagnostics to Present at the 29th Annual Piper Jaffray Healthcare …” on November 15, 2017, also Seekingalpha.com published article titled: “Accelerate Diagnostics’ (AXDX) CEO Lawrence Mehren on Q3 2017 Results …”, Globenewswire.com published: “Accelerate Diagnostics Welcomes Dr. Charles Watts to its Board of Directors” on November 16, 2017. More interesting news about Accelerate Diagnostics Inc (NASDAQ:AXDX) was released by: Globenewswire.com and their article: “Accelerate Diagnostics reports Q3 2017 financial results” with publication date: